AUA Guidelines on Advanced Prostate Cancer Webcast (2023)
Incorporating the most updated AUA/ASTRO/SUO APC Guidelines, this course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic hormone sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC). The course will include germline testing, PSMA positron emission tomography imaging, and the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. The role of treatment intensification in mHSPC will be discussed. The course will also cover nonmetastatic CRPC and treatment for metastatic CRPC. The use of sequencing, combination therapy, germline and somatic testing, precision medicine with PARP inhibitors and theranostics will also be discussed. The course will also cover emerging salvage therapies for CRPC.
Independent educational grant support provided by:
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Merck & Co., Inc.
- Pfizer, Inc.
At the conclusion of this activity, participants will be able to:
- Identify appropriate use of genetic testing and genetic counseling.
- Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
- Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy.
- Discuss treatment intensification in mHSPC.
- Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing.
|Name||Company Name||Relationship Type||End Date|
|David F. Jarrard, MD||None|
|William L. Lowrance ,MD||None|
|Adam S. Kibel, MD||Profound||Consultant or Advisor||Current|
|Janssen||Consultant or Advisor||Current|
|Bristol-Myers Squibb||Other-Data Safety Monitoring Board||Current|
|Merck||Consultant or Advisor||10/24/2022|
|Bayer||Consultant or Advisor||2/21/2022|
|Exlexis||Consultant or Advisor||7/8/2022|
|Myovant||Consultant or Advisor||5/6/2022|
|Blue Earth||Consultant or Advisor||10/24/2022|
|Roche||Consultant or Advisor||10/24/2022|
|Cellvax||Consultant or Advisor||Current|
|Candel||Other-On their DSMC.||Current|
|Michael S. Cookson, MD, MHA||TesoRx Pharma LLC||Consultant or Advisor||9/15/2021|
|Bayer Healthcare Pharmaceuticals||Consultant or Advisor||12/1/2021|
|Pfizer||Consultant or Advisor||Current|
|Prokarium||Consultant or Advisor||10/26/2022|
|Propella||Consultant or Advisor||10/19/2022|
|Pacifice Edge Diagnostics||Consultant or Advisor||12/1/2021|
|Nonagen Bioscience Corp.||Consultant or Advisor||7/11/2023|
|Janssen Pharmaceuticals||Consultant or Advisor||11/30/2022|
|Lantheus||Consultant or Advisor||9/24/2022|
EDUCATION COUNCIL DISCLOSURES:
COI REVIEW WORKGROUP DISCLOSURES:
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2023
Expiration Date: May, 2024
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation